All Coverage

computerized illustrations of HIV and COVID-19
Adverse Events & Comorbidities

CROI 2022 Data Bites: HIV and COVID-19

Larry Buhl; Myles Helfand
News
5 Min Read

New findings on COVID-19 vaccine efficacy in people living with HIV—as well as a suggestion that TDF may have some protective effect against severe COVID outcomes among older PLWH.

computerized illustrations of HIV and COVID-19
Adverse Events & Comorbidities

CROI 2022 Data Bites: HIV and COVID-19

Larry Buhl; Myles Helfand
News
5 Min Read

New findings on COVID-19 vaccine efficacy in people living with HIV—as well as a suggestion that TDF may have some protective effect against severe COVID outcomes among older PLWH.

Putting test tubes into the holder
Adverse Events & Comorbidities

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

Barbara Jungwirth; Myles Helfand
News
1 Min Read

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

Putting test tubes into the holder
Adverse Events & Comorbidities

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

Barbara Jungwirth; Myles Helfand
News
1 Min Read

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

De-Simplifying Single-Tablet Regimens for HIV Treatment Img
Antiretroviral Therapy

De-Simplifying Single-Tablet Regimens for HIV Treatment

Sean R. Hosein; Canadian AIDS Treatment Information Exchange
8 Min Read

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

De-Simplifying Single-Tablet Regimens for HIV Treatment Img
Antiretroviral Therapy

De-Simplifying Single-Tablet Regimens for HIV Treatment

Sean R. Hosein; Canadian AIDS Treatment Information Exchange
8 Min Read

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial Img
Abacavir/Lamivudine (Epzicom, Kivexa)

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial

Polly Clayden; HIV i-Base
News
2 Min Read

Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial Img
Abacavir/Lamivudine (Epzicom, Kivexa)

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial

Polly Clayden; HIV i-Base
News
2 Min Read

Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.

psax_150x150.gif
Antiretroviral Therapy

HIV Drug Development Pipeline Update, Fall 2014 Edition

Myles Helfand
Slideshow

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

psax_150x150.gif
Antiretroviral Therapy

HIV Drug Development Pipeline Update, Fall 2014 Edition

Myles Helfand
Slideshow

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

HIV Care Cost & Access

GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.

GlaxoSmithKline
News
3 Min Read

Research Triangle Park -- GlaxoSmithKline [NYSE: GSK] announced today the launch of a new Patient Savings Card designed to help eligible patients improve compliance with their HIV regimens by reducing their out-of-pocket expenses for GSK HIV medica...

HIV Care Cost & Access

GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.

GlaxoSmithKline
News
3 Min Read

Research Triangle Park -- GlaxoSmithKline [NYSE: GSK] announced today the launch of a new Patient Savings Card designed to help eligible patients improve compliance with their HIV regimens by reducing their out-of-pocket expenses for GSK HIV medica...

Adverse Events & Comorbidities

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

Mark Wainberg, Ph.D.
2 Min Read

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

Adverse Events & Comorbidities

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

Mark Wainberg, Ph.D.
2 Min Read

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

Lamivudine (3TC, Epivir)

Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine

Edwin DeJesus, M.D.
4 Min Read

The combination of abacavir (ABC, Ziagen) and lamivudine (3TC, Epivir), given once daily (QD) or twice daily (BID), or as a fixed-dose combination (FDC), has been extensively studied in antiretroviral-naive patients as part of non-nucleoside reverse ...

Lamivudine (3TC, Epivir)

Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine

Edwin DeJesus, M.D.
4 Min Read

The combination of abacavir (ABC, Ziagen) and lamivudine (3TC, Epivir), given once daily (QD) or twice daily (BID), or as a fixed-dose combination (FDC), has been extensively studied in antiretroviral-naive patients as part of non-nucleoside reverse ...

Abacavir/Lamivudine (Epzicom, Kivexa)

Understanding Two New Once-a-Day Combinations: Truvada and Epzicom

Daniel S. Berger, M.D.; Positively Aware
9 Min Read

Introduction

Sexy new drugs have appeared ahead of schedule on drugstore shelves and with much fanfare. Gilead Sciences, gained approval for Truvada, a combination pill of Viread plus Emtriva. GlaxoSmithKline (GSK), have combined Epivir and Ziagen ...

Abacavir/Lamivudine (Epzicom, Kivexa)

Understanding Two New Once-a-Day Combinations: Truvada and Epzicom

Daniel S. Berger, M.D.; Positively Aware
9 Min Read

Introduction

Sexy new drugs have appeared ahead of schedule on drugstore shelves and with much fanfare. Gilead Sciences, gained approval for Truvada, a combination pill of Viread plus Emtriva. GlaxoSmithKline (GSK), have combined Epivir and Ziagen ...

Abacavir/Lamivudine (Epzicom, Kivexa)

New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D.

John S. James; AIDS Treatment News
10 Min Read

Dr. Cal Cohen is the research director of the Community Research Initiative of New England, teaches at Harvard Medical School in Boston, and is affiliated with Harvard Vanguard Medical Associates. Dr. Cohen spoke with AIDS Treatment News on September...

Abacavir/Lamivudine (Epzicom, Kivexa)

New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D.

John S. James; AIDS Treatment News
10 Min Read

Dr. Cal Cohen is the research director of the Community Research Initiative of New England, teaches at Harvard Medical School in Boston, and is affiliated with Harvard Vanguard Medical Associates. Dr. Cohen spoke with AIDS Treatment News on September...

Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

Two New Fixed-Dose Combinations Approved

U.S. Food and Drug Administration
News
2 Min Read

FDA announced approval today, August 2, 2004, of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. The FDCs are GlaxoSmithKline's EPZICOMTM (abacavir/lamivudin...

Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

Two New Fixed-Dose Combinations Approved

U.S. Food and Drug Administration
News
2 Min Read

FDA announced approval today, August 2, 2004, of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. The FDCs are GlaxoSmithKline's EPZICOMTM (abacavir/lamivudin...

Tenofovir Disoproxil Fumarate (Viread)

Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir

Frank S. Rhame, M.D.
3 Min Read

Background

At the 2nd International AIDS Society Conference in Paris in the summer of 2003, we first learned of the unexpected weakness of the triple-nucleoside regimen consisting of tenofovir (TDF, Viread) plus lamivudine (3TC, Epivir) plus abacavi...

Tenofovir Disoproxil Fumarate (Viread)

Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir

Frank S. Rhame, M.D.
3 Min Read

Background

At the 2nd International AIDS Society Conference in Paris in the summer of 2003, we first learned of the unexpected weakness of the triple-nucleoside regimen consisting of tenofovir (TDF, Viread) plus lamivudine (3TC, Epivir) plus abacavi...